By Sabela Ojea
Shares of BioVie on Tuesday climbed after the company said the last of 400 patients completed treatment in its multicenter phase 3 study to treat Alzheimer’s disease.
At 2:05 pm E.T., shares were up 12% at $3.65. The stock has, however, plunged 53% since the year started.
The clinical-stage company it remains on track to announce topline data on the cognitive and functional assessments by the end of November.
“We are cautiously optimistic about what to expect later this year based on data previously seen from our Phase 2 exploratory biomarker trial,” Chief Executive Cuong Do said.
Write to Sabela Ojea at [email protected]; @sabelaojeaguix
Read the full article here
